Wyeth, Advanced Life In Pact To Develop Antibiotic For Southeast Asia
This article was originally published in PharmAsia News
Executive Summary
Wyeth is investing $100 million in a collaboration with Advanced Life Sciences, Holdings, also of the U.S., to develop and market a pneumonia antibiotic for the Asia Pacific region, but excluding Japan. Advanced Life licensed the cethromycin drug from Abbott Laboratories, which has applied for approval in the U.S. and Japan. The drug is one of a class of ketolide antibiotics prescribed to prevent infectious bacteria from becoming resistant to drugs. Advanced Life and Wyeth intend to develop the drug to treat community-acquired pneumonia. (Click here for more
You may also be interested in...
Wyeth Plans To Market Second-Generation Ketolide In Asia Pacific Region
HONG KONG - Wyeth plans to market a second-generation ketolide in the Asia Pacific region, noting that serious side effects associated with the first generation of the new type of antibiotic have not surfaced
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.